Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03360890
Title Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

salivary gland cancer

thyroid gland cancer

Therapies

Docetaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.